Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.
about
Lipotoxicity in the pancreatic beta cell: not just survival and function, but proliferation as well?Lipotoxicity disrupts incretin-regulated human β cell connectivityInadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes MellitusDifferential acute postprandial effects of processed meat and isocaloric vegan meals on the gastrointestinal hormone response in subjects suffering from type 2 diabetes and healthy controls: a randomized crossover study.Adaptation of β-Cell and Endothelial Function to Carbohydrate Loading: Influence of Insulin ResistancePancreatic Beta Cell G-Protein Coupled Receptors and Second Messenger Interactions: A Systems Biology Computational AnalysisEffect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.Glucagon-like peptide-1: modulator of β-cell dysfunction and death.Role of pancreatic transcription factors in maintenance of mature β-cell function.Exendin-4 Exhibits Enhanced Anti-tumor Effects in Diabetic Mice.Lipotoxicity impairs incretin signalling.Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.GLP-1 response to sequential mixed meals: influence of insulin resistance.Acute Changes in Non-esterified Fatty Acids in Patients with Type 2 Diabetes Receiving Bariatric Surgery.The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis.Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat dietEffects of supplementation with omega-3 on insulin sensitivity and non-esterified free fatty acid (NEFA) in type 2 diabetic patients
P2860
Q26866054-DC7D9911-BCC7-4175-81B6-985E95DE9944Q30634760-ACF318E4-7648-477E-B2C3-193C592E4E02Q33775600-6D7E6FE7-6BDA-488F-B035-83E4291F0006Q34184127-0BDECAB9-D718-405C-BE5D-EBD4F4E46814Q35769553-CE94CF70-65A3-46D7-8E64-F6345C31BEC4Q36006492-AECF87AA-BB64-4196-BE39-42859E21D3CEQ37064893-F7B537F5-0A62-4A16-9624-65CAA1802885Q38134115-124141E0-1290-4354-9359-B4583A91B26BQ38385473-DD18BDB6-4694-4F7F-AE73-6FCE2741E593Q38703807-0F380546-CD01-45FE-B63A-642260D198F1Q42534866-5AFF09A0-7C23-464B-8F96-778BBEF98ABDQ46945180-CF296068-A631-4DF2-A744-855E4097917CQ47621594-EC1CC095-2DFB-4D0B-8390-B01B17BEF8F9Q48109097-150385E5-F08F-4252-B65B-6C79DEBBE972Q51093729-CFBB1278-06EC-4E26-9CA4-8A5FB7769E4BQ57591304-EE384C1C-E7CE-44EF-A3A8-9BA8BF54C94EQ58200110-A1D62AD9-3740-4D69-A506-31BCD787B8D6
P2860
Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacological reduction of N ...... l in mouse models of diabetes.
@ast
Pharmacological reduction of N ...... l in mouse models of diabetes.
@en
type
label
Pharmacological reduction of N ...... l in mouse models of diabetes.
@ast
Pharmacological reduction of N ...... l in mouse models of diabetes.
@en
prefLabel
Pharmacological reduction of N ...... l in mouse models of diabetes.
@ast
Pharmacological reduction of N ...... l in mouse models of diabetes.
@en
P2093
P2860
P50
P1433
P1476
Pharmacological reduction of N ...... ll in mouse models of diabetes
@en
P2093
P2860
P2888
P304
P356
10.1007/S00125-012-2776-X
P577
2012-11-28T00:00:00Z